Latest news with #Interlace
Cision Canada
5 days ago
- Business
- Cision Canada
Interlace Launches White-Label Card Solutions to Power Personalized Enterprise Payments
SINGAPORE, June 16, 2025 /CNW/ -- As digital transformation accelerates, enterprises are increasingly challenged by inefficient payment systems — ranging from high cross-border transaction fees and complex multi-currency settlements to the disconnect between crypto and traditional finance, as well as slow, manual employee reimbursements. To address these pressing issues, enterprise bank cards have evolved into essential tools for streamlining fund management and expanding payment use cases. More than just transactional instruments, these cards are now powerful brand assets — driving customer loyalty and unlocking new revenue streams. In response to this shift, white-label card solutions with customizable branding have emerged as a critical innovation. Interlace, an advanced fintech platform bridging Web2 and Web3, is at the forefront of this evolution. The company has launched a comprehensive CaaS (Card-as-a-Service) platform paired with white-label issuance capabilities. Designed to be fast, user-friendly, and secure, Interlace's solution empowers Web3 companies, crypto exchanges, OTA travel platforms, AI startups, and cross-border trade businesses to deliver seamless, branded payment experiences tailored to their operational needs and customer expectations. I. What Is a White-Label Card? A white-label card allows enterprises to customize its design, such as adding a brand logo or tailoring the card appearance, giving their bank cards a distinct and branded look. The core value of a white-label card lies in: Brand Sovereignty: Fostering Customer Loyalty White-label cards support brand customization, enhancing user recognition. For internal staff, using cards printed with their company's brand boosts a sense of belonging and loyalty. For end users, white-label cards project a strong brand image and instill confidence in transactions. Growth: Increasing Brand Exposure and Business Development In addition to providing a secure and reliable branded payment experience, white-label cards streamline financial operations and strengthen partnerships. As daily business payment tools, physical cards with corporate logos offer repeated brand exposure, helping expand customer bases and drive business growth. II. Traditional Card Issuance: Hidden Barriers to Personalized Enterprise Payments Despite the clear benefits of white-label cards, the traditional path to launching customized card programs is riddled with hurdles in terms of technology, compliance, and operations: 1. Dual Barriers of Compliance and Qualification Card Networks and Banks: Enterprises must engage with card networks such as Visa or Mastercard to apply for membership or find issuing bank partners — this involves strict due diligence, high deposits, and lengthy negotiations. Self-developing a card system involves complex integrations and is limited by banking system capabilities and timelines. High Compliance Costs: For multi-currency or cross-border transactions, enterprises must navigate regional financial regulations and implement AML, KYC, and anti-fraud systems, greatly increasing compliance costs. 2. Heavy Technical and Operational Burdens High System Development Costs: Building systems for card lifecycle management (issuance, activation, loss reporting, etc.), transaction clearing and settlement, risk control, and account systems requires major investment in tech teams and long-term maintenance. Lack of Core Financial Infrastructure: Without direct connections to card networks, clearing systems, and bank payment systems, enterprises face inefficiencies in transaction processing, long settlement cycles, and opaque fees. 3. Lack of Agility and Innovation Slow Response Times: Traditional card issuance processes are lengthy — often taking months — making it difficult to adapt quickly to market demands or innovative business needs. Low Degree of Customization: Standard offerings from issuing banks or card networks often fall short in meeting specific enterprise needs around design, BIN selection, card privileges, and API integration depth. These obstacles have become high walls preventing enterprises from quickly deploying customized payment capabilities, optimizing fund flows, or enhancing user experiences. There is a pressing need for a more agile, lightweight, and cost-efficient solution. Interlace White-Label Solution: The Power of Brand + CaaS As an innovative platform focused on financial infrastructure, Interlace has a deep understanding of the challenges enterprises face in customizing payment solutions.. It has launched a pioneering CaaS (Card as a Service) + white-label card solution that enables personalized card issuance through open APIs and advanced customization features. 1. Full-Stack Financial Infrastructure, Ready to Use As a Principal Member of Visa Hong Kong, Interlace has direct issuing qualifications and integrates deeply with global clearing networks like VISA, ensuring efficient, stable, and compliant transactions. It offers over 30 card BINs and multi-currency account and settlement capabilities (USD, EUR, etc.), solving cross-border payment challenges. Developer-Friendly APIs: Interlace provides comprehensive, well-documented Open APIs. Enterprises can integrate the issuing system in as little as 14 days, combining recharge, transaction management, billing, risk control, and compliance into a seamless workflow. 2. Brand-Centric Customization to Fuel Innovation With Interlace's white-label solution, enterprises gain full control over card design — adding logos and custom visuals (compliant with network standards) to create unique branded cards. Whether for internal staff or end customers, the card becomes a mobile brand ambassador. By integrating Interlace CaaS, enterprises can issue both virtual and physical cards as needed. These can be linked to Apple Pay, Google Wallet, and other major wallets for online transactions, as well as used at offline POS terminals — covering all payment scenarios and maximizing convenience and brand exposure. 3. Intelligent Risk Control and Global Compliance On the security front, Interlace incorporates compliance screening, intelligent risk controls, and fund custody. Its systems cover multiple jurisdictions' AML/KYC requirements and data privacy protections and meet PCI DSS Level 1 standards. With Interlace's compliance resources, enterprises significantly reduce technical, time, and financial burdens, allowing them to focus on core business. Turning Cards into Engines of Brand Growth As payments become central to user experience, a white-label card carrying a company's brand has evolved far beyond a payment tool. It is a symbol of employee identity, a business card that builds customer trust, a bridge between online and offline transactions, and a hidden engine of business growth. Interlace's CaaS + white-label card solution, through its full-stack financial infrastructure, flexible brand customization, compliance-ready security, and open API ecosystem, empowers enterprises to build personalized payment experiences for the Web3 era — reducing costs, enhancing agility, and accelerating time to market. It helps optimize payment operations, reinforce brand identity, and unlock new growth potential.
Yahoo
10-06-2025
- Health
- Yahoo
Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
Grant forms part of £1.2M project to customise Tagomics' multiomic profiling platform for early detection of colorectal cancer Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's InterlaceTM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: "We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes." Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: "The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes." For more information about Tagomics, please visit: View source version on Contacts Media: Francesca Sign in to access your portfolio
Business Wire
10-06-2025
- Business
- Business Wire
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
CAMBRIDGE, England--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's Interlace TM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: 'We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: 'The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes.'
Yahoo
10-06-2025
- Business
- Yahoo
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
Grant forms part of £1.2M project to customise Tagomics' multiomic profiling platform for early detection of colorectal cancer Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's InterlaceTM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: "We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes." Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: "The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes." For more information about Tagomics, please visit: View source version on Contacts Media: Francesca Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
